Colleen Deturk, NP
Obstetrics & Gynecology · Newark, DENPI 1801873062
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,704 of the $3,619 with a category attached, or 74.7%. 17 manufacturers reported payments, led by Axonics, Inc. at 37.1% of the total. Reporting peaked in 2024 at $1,675 and has fallen 72.8% since, to $455 in 2025. Among obstetrics & gynecology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $30.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$1K
- Medtronic$561
- Astellas Pharma US Inc$431
- Sumitomo Pharma America, Inc.$313
- AbbVie$235
- Millicent US Inc$141
- plus $596 from 11 others
What the payments were for
- Travel & lodging$71520%
- Food & beverage$2,70475%
- Education$1855%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 16 | $1,341 |
| Medtronic | 16 | $561 |
| Astellas Pharma US Inc | 13 | $431 |
| Sumitomo Pharma America, Inc. | 23 | $313 |
| AbbVie | 11 | $235 |
| Millicent US Inc | 9 | $141 |
| Mission Pharmacal Company | 7 | $119 |
| Coloplast | 5 | $119 |
| Urovant Sciences Inc | 4 | $80 |
| Boston Scientific | 3 | $68 |
| Therapeuticsmd, Inc. | 3 | $60 |
| Pfizer | 3 | $51 |
| Sage Therapeutics, LLC | 1 | $25 |
| Bluewind Medical | 1 | $24 |
| 180 Medical, Inc. | 1 | $22 |
| Provepharm Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,619 in reported general payments places this provider in the 90th percentile of 139 obstetrics & gynecology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 161 | $143,543 |
| GemtesaVibegron | 41 | $35,177 |
| Estradiol | 150 | $9,964 |
| EstringEstradiol | 17 | $9,073 |
| Methenamine Hippurate | 64 | $6,053 |
| Trospium Chloride ErTrospium Chloride | 21 | $5,125 |
| Trospium Chloride | 23 | $1,172 |
| Solifenacin Succinate | 34 | $1,165 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $811 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 58 | $632 |
| Baclofen | 13 | $178 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $136 |
| Cephalexin | 16 | $96 |
| Amoxicillin | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $431 | $143,543161 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $313 | $35,17741 claims |
| PfizerEstring | $51 | $9,07317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 139 obstetrics & gynecology providers in Delaware.
Other obstetrics & gynecology in Newark
- Anthony BellNewark$17K
- Richard DermanNewark$14K
- Gordon OstrumNewark$4K
- Patricia CiranniNewark$3K
- Michelle PacisNewark$3K
- Gregory DemeoNewark$3K
- Jose PicazoNewark$2K
- David FinkNewark$2K
- Stefanie MarshallNewark$2K
- Faith BroschNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.